Recce hits milestone in Phase I/II trial for UTIs and urosepsis

Reece’s pipeline includes three synthetic polymer anti-infectives for bacteria and viruses.

Robert Barrie March 19 2024

Reece Pharmaceuticals has completed the dosing of a cohort of healthy participants in its phase I/II trial evaluating its REECE327 (R327) anti-infective.

The study, which consists of four cohorts each with four participants, will assess R327 at different doses, intravenous infusion times, and concentrations. The primary endpoint of the trial is the safety and tolerability of R327.

The Australia-based pharma company said recruitment for the next cohort is already underway, as it looks to use data to inform a Phase II trial. The Phase II trial will evaluate the potential of R327 as a frontline treatment for patients with urinary tract infections (UTIs) or urosepsis. UTIs and urosepsis are usually a result of bacteria entering the urinary tract.

Reece specialises in developing anti-infective drugs in what it says are needed to address antibiotic-resistant superbugs and viral pathogens.

The company’s pipeline includes three synthetic polymer anti-infectives. R327 is joined by R435 and R529 for the treatment of bacterial and viral infections respectively.

R327 was awarded Qualified Infectious Disease Product designation by the US Food and Drug Administration (FDA). The drug was labelled for fast-track designation and could be in line for 10 years of market exclusivity if approved.

Antibiotic resistance is increasing, with rising concern in healthcare highlighting the need for novel treatments. The topic was discussed at the recent World Economic Forum Meeting 2024, with calls for innovative, alternative therapies.

Some healthcare organisations, like England’s National Health Service (NHS), have started introducing new pricing models to lure big pharmaceutical companies away from volume-based sales to tackle antimicrobial resistance.  

Reece’s CEO James Graham said: “Completing dosing of our latest cohort marks another milestone in our journey toward advancing R327 as a potential frontline treatment for patients with UTIs or urosepsis.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close